Results 151 to 160 of about 115,987 (377)

Inflammatory Serine Proteases Play a Critical Role in the Early Pathogenesis of Diabetic Cardiomyopathy. [PDF]

, 2019
BACKGROUND/AIMS: Diabetic cardiomyopathy (DCM) is characterized by structural and functional alterations that can lead to heart failure. Several mechanisms are known to be involved in the pathogenesis of DCM, however, the molecular mechanism that links ...
Barbery, Carlos, Chaki, Shaswati, Guo, Xinji, Kolpakov, Mikhail A, Qi, Zhao, Rafiq, Khadija, Sabri, Abdelkarim, Sarkar, Amrita, Shukla, Sanket K, Sikder, Kunal   +9 more
core   +1 more source

Association between glucagon‐like peptide‐1 receptor agonists and risk of dementia in older adults with type 2 diabetes: A target trial emulation

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Type 2 diabetes (T2D) is associated with increased dementia risk, but comparative data across newer glucose‐lowering therapies remain limited. We examined whether the initiation of GLP‐1 receptor agonists (GLP‐1 RAs) was associated with incident dementia compared with DPP4 inhibitors (DPP4is) and SGLT2 inhibitors (SGLT2is) in older adults ...
Ting Zhou, Huilin Tang, Bingyu Zhang, Dazheng Zhang, Yiwen Lu, Lu Li, Jiajie Chen, Yong Chen, David A. Asch, Yong Chen   +9 more
wiley   +1 more source

Literature‐informed ensemble machine learning for three‐year diabetic kidney disease risk prediction in type 2 diabetes: Development, validation, and deployment of the PSMMC NephraRisk model

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Introduction Diabetic kidney disease (DKD) and diabetic nephropathy (DN) affect around 40% of diabetic patients but lack accurate risk prediction tools that include social determinants and demographic complexity. We developed and validated an ensemble machine learning model for three‐year DKD/DN risk prediction with deployment readiness ...
Ayla M. Tourkmani, Turki J. Al‐Harbi, Ahmad Abdullah Alghamdi, Ibrahim M. Youzghadli, Faris Saad Alosaimi, Ahmed Y. Azzam   +5 more
wiley   +1 more source

Hypoglycemic Coma in a Hemodialysis Patient Receiving Blood Glucose-Lowering Therapy With the Single Agent Teneligliptin

Clinical Medicine Insights: Case Reports, 2018
Blood glucose management in patients undergoing dialysis is clinically challenging. In this population, most conventional oral hypoglycemic agents are contraindicated, especially from the perspective of pharmacokinetics. Dipeptidyl peptidase-4 inhibitors
Takumi Minezumi, Shin-ichi Takeda, Yusuke Igarashi, Kentaro Sato, Yoshiaki Murakami, Daisuke Nagata   +5 more
doaj   +1 more source

Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim This study evaluated the efficacy and safety of empagliflozin 10 and 25 mg compared to placebo as add‐on treatment for people with type 2 diabetes mellitus (T2DM) uncontrolled after ≥8 weeks of treatment with metformin and sitagliptin. Materials and Methods A randomised, double‐blind, multicentre, therapeutic confirmatory, phase 3 clinical
Seung‐Hwan Lee, Kyung Ah Han, Eun‐Gyoung Hong, Jun Goo Kang, Choon Hee Chung, Jong Chul Won, Eon Ju Jeon, Jung‐Hwan Cho, Ho Chan Cho, Sin Gon Kim, Eun Seok Kang, So Hun Kim, Hae Jin Kim, In‐Kyung Jeong, Sung Wan Chun, Young Min Cho   +15 more
wiley   +1 more source

The multiple actions of dipeptidyl peptidase 4 (DPP-4) and its pharmacological inhibition on bone metabolism: a review

Diabetology & Metabolic Syndrome
Background Dipeptidyl peptidase 4 (DPP-4) plays a crucial role in breaking down various substrates. It also has effects on the insulin signaling pathway, contributing to insulin resistance, and involvement in inflammatory processes like obesity and type ...
L. M. Pechmann, F. I. Pinheiro, V. F. C. Andrade, C. A. Moreira   +3 more
doaj   +1 more source

Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies [PDF]

, 2016
Ling Li, Sheyu Li, Ke Deng, Jiali Liu, Per Olav Vandvik, Pujing Zhao, Longhao Zhang, Jiantong Shen, Małgorzata M Bała, Zahra Sohani, Evelyn M. Wong, Jason W. Busse, Shanil Ebrahim, Germán Málaga, Lorena P Rios, Yingqiang Wang, Qunfei Chen, Gordon Guyatt, Xin Sun   +18 more
openalex   +1 more source

Review for "Lower Risk of Hospitalisation for Heart Failure, Kidney Disease and Death with Sodium Glucose Co‐Transporter ‐2 Compared to Dipeptidyl Peptidase‐4 Inhibitors in Type 2 Diabetes Regardless of Prior Cardiovascular or Kidney Disease: A Retrospective Cohort Study in UK Primary Care"

, 2021
Angel Wong
openalex   +1 more source

Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen-DQB1*03:01 [PDF]

, 2020
Arata Hibi, Yuto Kasahara, Y. Ishihara, Koichi Hata, Norihisa Hosokawa, Takahiko Nakagawa   +5 more
openalex   +1 more source

Comparison of cardiovascular outcomes and cardiometabolic risk factors between patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors: a meta-analysis [PDF]

, 2021
Siwen Wang, Ting Wu, Zhihong Zuo, Ping Jin, Xuan Luo, Meichun Deng   +5 more
openalex   +1 more source